SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.